Locations:
SearchOral immunotherapy drug is first of its kind
About 8% of U.S. children have a food allergy, and that number is on the rise. Avoiding the allergic trigger is recommended, but it’s not always possible.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Desensitization therapy, while not a cure, may alleviate some fear of accidental exposure by training the immune system to adapt.
In September 2019, an FDA expert panel recommended approval of a first-of-its-kind treatment — an oral immunotherapy medication to gradually build tolerance to peanut exposure.
In this video, learn more about why this therapy for peanut allergies is one of Cleveland Clinic’s Top 10 Medical Innovations for 2020.
Advertisement
Advertisement
Advanced software streamlines charting, supports deeper patient connections
How holding simulations in clinical settings can improve workflow and identify latent operational threats
Interactive Zen Quest experience helps promote relaxing behaviors
Cleveland Clinic and IBM leaders share insights, concerns, optimism about impacts
Cleveland Clinic partners with Palantir to create logistical command center
A Q&A with organizational development researcher Gina Thoebes
Cleveland Clinic transformation leader led development of benchmarking tool with NAHQ
Raed Dweik, MD, on change management and the importance of communication